230 related articles for article (PubMed ID: 24041906)
1. Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases.
Stokes NR; Thomaides-Brears HB; Barker S; Bennett JM; Berry J; Collins I; Czaplewski LG; Gamble V; Lancett P; Logan A; Lunniss CJ; Peasley H; Pommier S; Price D; Smee C; Haydon DJ
Antimicrob Agents Chemother; 2013 Dec; 57(12):5977-86. PubMed ID: 24041906
[TBL] [Abstract][Full Text] [Related]
2. In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.
Charrier C; Salisbury AM; Savage VJ; Moyo E; Forward H; Ooi N; Cheung J; Metzger R; McGarry D; Walker R; Cooper IR; Ratcliffe AJ; Stokes NR
J Antimicrob Chemother; 2016 Oct; 71(10):2831-9. PubMed ID: 27353465
[TBL] [Abstract][Full Text] [Related]
3. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase.
Bellon S; Parsons JD; Wei Y; Hayakawa K; Swenson LL; Charifson PS; Lippke JA; Aldape R; Gross CH
Antimicrob Agents Chemother; 2004 May; 48(5):1856-64. PubMed ID: 15105144
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds.
Grossman TH; Bartels DJ; Mullin S; Gross CH; Parsons JD; Liao Y; Grillot AL; Stamos D; Olson ER; Charifson PS; Mani N
Antimicrob Agents Chemother; 2007 Feb; 51(2):657-66. PubMed ID: 17116675
[TBL] [Abstract][Full Text] [Related]
5. Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.
Jakopin Ž; Ilaš J; Barančoková M; Brvar M; Tammela P; Sollner Dolenc M; Tomašič T; Kikelj D
Eur J Med Chem; 2017 Apr; 130():171-184. PubMed ID: 28246042
[TBL] [Abstract][Full Text] [Related]
6. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
Pan XS; Fisher LM
J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
[TBL] [Abstract][Full Text] [Related]
7. Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines.
Uria-Nickelsen M; Neckermann G; Sriram S; Andrews B; Manchester JI; Carcanague D; Stokes S; Hull KG
Int J Antimicrob Agents; 2013 Apr; 41(4):363-71. PubMed ID: 23305654
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects.
Ibrahim NM; Fahim SH; Hassan M; Farag AE; Georgey HH
Eur J Med Chem; 2022 Jan; 228():114021. PubMed ID: 34871841
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
Alt S; Mitchenall LA; Maxwell A; Heide L
J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
[TBL] [Abstract][Full Text] [Related]
10. Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
Ho SY; Wang W; Ng FM; Wong YX; Poh ZY; Tan SWE; Ang SH; Liew SS; Joyner Wong YS; Tan Y; Poulsen A; Pendharkar V; Sangthongpitag K; Manchester J; Basarab G; Hill J; Keller TH; Cherian J
Eur J Med Chem; 2018 Sep; 157():610-621. PubMed ID: 30125722
[TBL] [Abstract][Full Text] [Related]
11. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.
Reck F; Alm R; Brassil P; Newman J; Dejonge B; Eyermann CJ; Breault G; Breen J; Comita-Prevoir J; Cronin M; Davis H; Ehmann D; Galullo V; Geng B; Grebe T; Morningstar M; Walker P; Hayter B; Fisher S
J Med Chem; 2011 Nov; 54(22):7834-47. PubMed ID: 21999508
[TBL] [Abstract][Full Text] [Related]
12. An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.
Tiz DB; Skok Ž; Durcik M; Tomašič T; Mašič LP; Ilaš J; Zega A; Draskovits G; Révész T; Nyerges Á; Pál C; Cruz CD; Tammela P; Žigon D; Kikelj D; Zidar N
Eur J Med Chem; 2019 Apr; 167():269-290. PubMed ID: 30776691
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity.
Surivet JP; Zumbrunn C; Rueedi G; Hubschwerlen C; Bur D; Bruyère T; Locher H; Ritz D; Keck W; Seiler P; Kohl C; Gauvin JC; Mirre A; Kaegi V; Dos Santos M; Gaertner M; Delers J; Enderlin-Paput M; Boehme M
J Med Chem; 2013 Sep; 56(18):7396-415. PubMed ID: 23968485
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors.
D'Atanasio N; Capezzone de Joannon A; Di Sante L; Mangano G; Ombrato R; Vitiello M; Bartella C; Magarò G; Prati F; Milanese C; Vignaroli C; Di Giorgio FP; Tongiani S
PLoS One; 2020; 15(2):e0228509. PubMed ID: 32074119
[TBL] [Abstract][Full Text] [Related]
15. DNA Topoisomerases as Targets for Antibacterial Agents.
Hiasa H
Methods Mol Biol; 2018; 1703():47-62. PubMed ID: 29177732
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting DNA gyrase B (GyrB) and topoisomerse IV (ParE) inhibitors: A review.
Azam MA; Thathan J; Jubie S
Bioorg Chem; 2015 Oct; 62():41-63. PubMed ID: 26232660
[TBL] [Abstract][Full Text] [Related]
17. Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
Hossion AM; Zamami Y; Kandahary RK; Tsuchiya T; Ogawa W; Iwado A; Sasaki K
J Med Chem; 2011 Jun; 54(11):3686-703. PubMed ID: 21534606
[TBL] [Abstract][Full Text] [Related]
18. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
19. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2).
Singh SB; Kaelin DE; Wu J; Miesel L; Tan CM; Black T; Nargund R; Meinke PT; Olsen DB; Lagrutta A; Lu J; Patel S; Rickert KW; Smith RF; Soisson S; Sherer E; Joyce LA; Wei C; Peng X; Wang X; Fukuda H; Kishii R; Takei M; Takano H; Shibasaki M; Yajima M; Nishimura A; Shibata T; Fukuda Y
Bioorg Med Chem Lett; 2015 May; 25(9):1831-5. PubMed ID: 25851938
[TBL] [Abstract][Full Text] [Related]
20. New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.
Durcik M; Nyerges Á; Skok Ž; Skledar DG; Trontelj J; Zidar N; Ilaš J; Zega A; Cruz CD; Tammela P; Welin M; Kimbung YR; Focht D; Benek O; Révész T; Draskovits G; Szili PÉ; Daruka L; Pál C; Kikelj D; Mašič LP; Tomašič T
Eur J Med Chem; 2021 Mar; 213():113200. PubMed ID: 33524686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
